Citigroup’s AnaptysBio ANAB Stock Holding History

Citigroup’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-45,000	Closed	-$596K	–	5549
2024 Q4	$596K	Buy	+45,000	New	+$1.09M	﹤0.01%	3707
2024 Q3	–	Sell	-24,000	Closed	-$601K	–	5667
2024 Q2	$601K	Sell	24,000 -6,000	-20%	-$140K	﹤0.01%	3271
2024 Q1	$676K	Hold	30,000	–	–	﹤0.01%	3342
2023 Q4	$643K	Hold	30,000	–	–	﹤0.01%	3214
2023 Q3	$539K	Hold	30,000	–	–	﹤0.01%	3001
2023 Q2	$610K	Buy	+30,000	New	+$608K	﹤0.01%	3231
2020 Q2	–	Sell	-2,500	Closed	-$35K	–	7522
2020 Q1	$35K	Sell	2,500 -10,900	-81%	-$165K	﹤0.01%	6284
2019 Q4	$218K	Sell	13,400 -6,100	-31%	-$144K	﹤0.01%	5112
2019 Q3	$682K	Buy	19,500 +3,500	+22%	+$167K	﹤0.01%	4043
2019 Q2	$903K	Buy	16,000 +15,200	+1,900%	+$1.09M	﹤0.01%	3750
2019 Q1	$58K	Sell	800 -2,200	-73%	-$152K	﹤0.01%	6205
2018 Q4	$191K	Buy	3,000 +500	+20%	+$37.2K	﹤0.01%	5062
2018 Q3	$249K	Buy	+2,500	New	+$207K	﹤0.01%	5012

Other funds holding ANAB

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return

Citigroup's ANAB Position: Q3 2026 in Review

Citigroup reduced its AnaptysBio (ANAB) stake by 18% in Q3 2026, selling an estimated $1.02M and leaving 81,102 shares worth $4.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2264.

Citigroup first reported a position in ANAB in Q1 2017 and has held it in 39 quarters since. The position peaked at $23.2M in Q2 2025. 71 funds tracked by Wall St. Rank hold ANAB as of Q3 2026.

Citigroup held 81,102 shares of AnaptysBio worth $4.08M as of Q3 2026.
Citigroup sold 18,012 AnaptysBio shares in Q3 2026, an estimated $1.02M.
AnaptysBio made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2264 holding.
Citigroup first reported a position in AnaptysBio in Q1 2017 and has held it in 39 quarters since.
Citigroup's AnaptysBio position peaked at $23.2M in Q2 2025.
71 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.